With extensive interdisciplinary entrepreneurial experience and corporate management capabilities, he has 20 years of experience in Internet communication, finance and bio-medical industry.

◆ Co-founded iTalkBB in 2004, which business covers millions of users around the world and has grew to become the leading Internet communication brand among Chinese communities in North America and Australia

◆ 7 years of working experience in the banking industry for Capital One and GD Capital

◆ MBA, HEC Paris School of Management

Henry S. Friedman Professor of Neuro-Oncology at Duke University Medical Center; member of the American Society for Clinical Investigation (ASCI). His research field covers the discovery of various cancer driver genes related to the development of malignant tumors, mutation function research and targeted therapy.

◆ A pioneer in early cancer screening, molecular typing, targeted therapy and immunotherapy research; first to discover a series of glioma-related oncogenes, such as IDH1/2, TERT, CIC, FUBP1, PPM1D, SMARCAL1, etc.
◆ The inventor of BEAMing technology which has become a core technology for cfDNA detection such as digital PCR; was also first used in the field of cancer liquid biopsy.

◆ Published more than 100 papers, including in international authoritative academic journals such as NEJM, Science, Nature, and has applied for 18 US patents.

◆Won the only scientific team award from the American Association for Cancer Research (AACR) in 2014 and the Distinguished Professor Award at the Duke University School of Medicine in 2017.

◆ Ph.D. of Molecular and Cellular Biology of Columbia University; Postdoctoral Fellow of Johns Hopkins University under the tutelage of Professor Bert Vogelstein.

Over 16 years of experience in market operations and management in the healthcare and medical industry.

◆ General Manager of China and Vice President of North Asia for C. R. Bard Inc.; responsible for founding and leading Bard’s functions in North Asia.

◆ Marketing Director of Johnson & Johnson Medical China and Director of the Surgery Department of Johnson & Johnson Medical China; responsible for department’s P&L and management.

◆ MBA, William E. Simon Graduate School of Business Administration, University of Rochester.

A researcher and doctoral supervisor at the Chinese Academy of Medical Sciences Cancer Hospital, who has long been committed to the research of cancer genomics and its non-invasive biopsy technology.

◆ Completed genomic studies of various tumors such as pancreatic neuroendocrine tumors, and found new mutations related to telomere maintenance such as ATRX and TERT, which were listed as important markers by the WHO classification of tumours of the central nervous system.

◆ Published more than 20 research papers in Science, Nature Genetics, PNAS and other periodicals as the lead or correspondent author.

◆ Biological Chemistry doctor of Johns Hopkins Medicine, focusing on the mechanism of tumor genome and important cancer gene mutations in the team of world-renowned oncologist, Professor Bert Vogelstein.

More than 12 years of working experience at several international investment banks.

◆ Director of the Investment Banking Division at Deutsche Bank AG, Hong Kong in 2016-2018.

◆ Executive Director of the Investment Banking Division of Goldman Sachs (Asia) L.L.C from 2010 to 2016.

◆ Manager of Lehman Brothers (Hong Kong) and Nomura Securities in 2008-2010.

◆ Master’s degree from the National University of Singapore.

He has over two decades of experience in regulatory and managerial capacities related to medical devices and pharmaceutical industries.

◆ During his tenure at FDA, he has led a team of staff in premarket reviews and post-market compliance of IVD products and laboratory-developed tests (LDTs) for genetic testing, molecular cancer diagnostics, companion diagnostics, radiodosimetry, digital pathology and artificial intelligence devices. Some of his notable authorizations include: the first next generation sequencing (NGS)-based LDT as companion diagnostics (CDx) (Foundation Medicine FoundationFocus CDxBRCA); the first NGS-based CDx kit (ThermoFisher Oncomine Dx Target Test); the first NGS-based LDT for tumor profiling (MSK-IMPACT) and later on FoundationOne CDx); the first liquid biopsy test for NSCLC (Roche Cobas EGFR Mutation Test v2); and FDA’s only two approved cancer screening tests in the last decade (Exact Sciences’ Cologuard and Epigenomics’ Epi ProColon). Dr. Hu and his team have also won over 10 FDA-level group awards for outstanding contributions in FDA authorization of many such first-of-its-kind devices

◆ 10 years of product development experience in diagnostic and pharmaceutical industries, leading his teams to achieve outstanding results in biomarker discovery and diagnostic development

◆ Ph.D. of Veterinary Physiology & Pharmacology and M.S. of Reproductive Endocrinology，Ohio State University; Postdoctoral Fellow of Fox Chase Cancer Center

Victoria is a visionary global business leader with extensive management experience in a diversity of industries across North America and Asia. Her expertise has been well-demonstrated in the areas of experiential marketing with design thinking, business development and branding. Being a seasoned entrepreneur and a Fortune 500 corporate manager at different heights during her career, Victoria’s multi-faceted experience saw her leading many successful new product launches from conceptualization to delivery. She is especially accomplished in developing integrated branding and go-to-market growth strategies for high-tech products with deep knowledge in consumer insights.

Victoria holds a bachelor’s degree in hotel management from the University of South Carolina and Hotel Institute Montreux, Switzerland. GMP from Harvard Business School.

◆ Successful entrepreneur.

◆ 18 years of experience in hospitality management, internet and life sciences industries.

With over a decade of experience in the pharmaceutical industry, Lin Teng has strong interest and is passionately involved in cancer care research work. She has a proven track record of success in marketing and team management at top pharmaceutical companies focusing on oncology drugs.

◆ 7 years of experience in biomedical services sector, including with Roche and Eli-Lilly.

◆ Bachelor of Medicine, Shandong University.

With over 30 years of management experience at Fortune 500 companies, Cathy brings valuable knowledge and competence in overseas market expansion and team management to Genetron Health. She has led the Alcatel-Lucent’s overseas business operations. As part of Genetron Health’s senior management team, Cathy has spearheaded and participated in the successful wins of several major national and local government projects. She is also in charge of intellectual property rights and market entry strategies.

◆ Held key positions of sales and government affairs director as well as vice president of overseas markets at HP China, Ericsson, Alcatel.

◆ Shanghai Fudan University School of Management, University of Hong Kong MBA (International).

Kathleen is a well-rounded HR practitioner with extensive experience in banking, FMCG, logistics and consulting industries. She has demonstrated deep understanding and strong capability in organizational design, performance management, talent development, staff engagement, change management and HR transformation functions. She is also well-versed in talent pipeline, succession planning as well as corporate culture development.

◆ Over 20 years of experience in Human Resources. Prior to joining Genetron Health, she helmed the Human Resources Department at Standard Chartered Bank in China. During her eight years with the bank, she has worked closely with the country CEO and branch managers in rolling out HR initiatives across all 28 branches in China.

◆ Bachelor’s and master’s degree in biology, Peking University.